Literature DB >> 10073852

Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris.

W H Frishman1, S Glasser, P Stone, P C Deedwania, M Johnson, T D Fakouhi.   

Abstract

This multicenter, randomized, double-blind, parallel group, placebo lead-in, placebo-controlled study compared the antianginal and anti-ischemic effects of once-daily bedtime dosing of controlled-onset extended-release (COER-24) verapamil to a once-daily morning dosing of amlodipine +/- atenolol in patients with chronic stable angina. A total of 551 patients with exercise-induced myocardial ischemia and evidence of coronary artery disease were randomized to a 4-week, forced-dose titration treatment period with (1) COER-24 verapamil 240 mg titrated to 480 mg at bedtime (n = 173), (2) amlodipine 5 mg titrated to 10 mg/day (n = 149), (3) amlodipine 5 mg (titrated to 10 mg) plus atenolol 50 mg/day in the A.M. (n = 154), or (4) placebo (n = 75). Treadmill exercise tolerance testing (standard Bruce protocol), and 48-hour ambulatory electrocardiographic (Holter) monitoring were performed at the end of placebo lead-in and double-blind treatment. Each active treatment significantly improved symptom-limited exercise duration and time to moderate angina (p < or = 0.01 vs placebo). For patients with baseline ischemia, amlodipine resulted in a statistically significant increase in total duration of ischemic episodes compared with placebo, whereas COER-24 verapamil and amlodipine plus atenolol resulted in statistically significant decreases compared with placebo and amlodipine. Heart rate at onset of ischemic episodes and ST product were also significantly increased with amlodipine (p < 0.05) compared with either COER-24 or amlodipine plus atenolol. COER-24 and amlodipine alone or in combination with atenolol improved exercise capacity in patients with angina pectoris. COER-24 verapamil monotherapy or amlodipine plus atenolol combination therapy were more effective than amlodipine monotherapy in decreasing ambulatory myocardial ischemia, especially during the hours of 6 A.M. to 12 noon.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10073852     DOI: 10.1016/s0002-9149(98)00904-7

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

1.  Failure of magnesium to protect isolated cardiomyocytes from effects of hypoxia or metabolic poisoning.

Authors:  M M Gallagher; A P Allshire
Journal:  Clin Cardiol       Date:  2000-07       Impact factor: 2.882

2.  Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS: a retrospective study.

Authors:  Dorsey M Bass; Mary Prevo; Deborah S Waxman
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 3.  Silent myocardial ischemia: recent developments.

Authors:  Peter F Cohn
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

4.  Contrasting effects of verapamil and amlodipine on cardiovascular stress responses in hypertension.

Authors:  J D Lefrandt; J Heitmann; K Sevre; M Castellano; M Hausberg; M Fallon; A Urbigkeit; M Rostrup; E Agabiti-Rosei; K H Rahn; M Murphy; F Zannad; P J de Kam; A J Smit
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

Review 5.  How to use calcium antagonists in hypertension: putting the JNC-VI guidelines into practice. Joint National Committee for the Prevention, Detection, Evaluation and Treatment of High Blood Pressure.

Authors:  V Singh; J Christiana; W H Frishman
Journal:  Drugs       Date:  1999-10       Impact factor: 9.546

Review 6.  Beta-Blockers, Calcium Channel Blockers, and Mortality in Stable Coronary Artery Disease.

Authors:  Jose B Cruz Rodriguez; Haider Alkhateeb
Journal:  Curr Cardiol Rep       Date:  2020-01-29       Impact factor: 2.931

7.  Influence of the Circadian System on Disease Severity.

Authors:  Mikhail Litinski; Frank Ajl Scheer; Steven A Shea
Journal:  Sleep Med Clin       Date:  2009-06-01

Review 8.  Antagonist molecules in the treatment of angina.

Authors:  Ashish K Gupta; David Winchester; Carl J Pepine
Journal:  Expert Opin Pharmacother       Date:  2013-09-18       Impact factor: 3.889

Review 9.  Drug treatment of stable angina pectoris in the elderly: defining the place of calcium channel antagonists.

Authors:  Sanjay Kumar; Roger J C Hall
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 10.  Management of Angina Post Percutaneous Coronary Intervention.

Authors:  Jose B Cruz Rodriguez; Subrata Kar
Journal:  Curr Cardiol Rep       Date:  2020-01-21       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.